...
首页> 外文期刊>Gynecologic Oncology: An International Journal >Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study
【24h】

Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study

机译:妇科肿瘤小组研究:铂和紫杉烷类化学疗法治疗晚期卵巢癌女性中ABCB1,ABCC2和ABCG2基因的常见变异和临床结果

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: Efflux transporters of the ATP-binding cassette (ABC) family are major determinants of chemoresistance in tumor cells. This study examined associations between functional variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes in patients with epithelial ovarian/primary peritoneal cancer (EOC/PPC) following platinum and taxane-based chemotherapy. Methods: Sequenom iPLEXTMGOLD Assay and MALDI-TOF platform were used to genotype the non-synonymous G2677T/A (rs2032582; encoding Ala893Ser/Thr) and synonymous C3435T (rs1045642; encoding Ile1145Ile) variants in ABCB1, the non-synonymous G1249A variant in ABCC2 (rs2273697; encoding Val417Ile), and the non-synonymous C421A variant in ABCG2 (rs2231142; encoding Q141K, Gln141Lys) in normal DNA from up to 511 women in Gynecologic Oncology Group (GOG) phase III trials, GOG-172 or GOG-182. Progression-free survival (PFS) and overall survival (OS) were analyzed in relation to genetic polymorphisms using Kaplan-Meier and Cox proportional hazards model. Results: The C421A variant (CA + AA versus CC) in ABCG2 was associated with a 6-month longer median PFS (22.7 versus 16.8 months, p = 0.041). In multivariate analysis, patients with variant genotypes were at a reduced risk of disease progression (hazard ratio [HR] = 0.75, 95% confidence interval [CI] = 0.59-0.96, p = 0.022). The association between C421A and OS was not statistically significant (HR = 0.88, 95% CI = 0.67-1.15, p = 0.356). None of the other variants measured in either ABCB1 or ABCC2 was associated with PFS or OS. Conclusion: The C421A variant in ABCG2, previously shown to be associated with enhanced protein degradation and drug sensitivity, was associated with longer PFS in advanced stage EOC/PPC patents treated with platinum + taxane-based chemotherapy. This finding requires further validation.
机译:目的:ATP结合盒(ABC)家族的外向转运蛋白是肿瘤细胞化学耐药性的主要决定因素。这项研究检查了铂和紫杉烷类化疗后上皮性卵巢/原发性腹膜癌(EOC / PPC)患者的ABCB1,ABCC2和ABCG2基因功能变异与临床结局之间的关联。方法:使用Sequenom iPLEXTMGOLD分析法和MALDI-TOF平台对ABCB1中的非同义G2677T / A(rs2032582;编码Ala893Ser / Thr)和同义C3435T(rs1045642;编码Ile1145Ile)变体进行基因分型,在非同义AB2CC中(rs2273697;编码Val417Ile),以及ABCG2中的非同义C421A变体(rs2231142;编码Q141K,Gln141Lys),来自正常妇科的DNA中来自多达511位妇科肿瘤学组(GOG)III期试验,GOG-172或GOG-182的女性。使用Kaplan-Meier和Cox比例风险模型分析了与基因多态性相关的无进展生存期(PFS)和总生存期(OS)。结果:ABCG2中的C421A变体(CA + AA对CC)与中位PFS延长6个月相关(22.7对16.8个月,p = 0.041)。在多变量分析中,具有不同基因型的患者的疾病进展风险降低(危险比[HR] = 0.75,95%置信区间[CI] = 0.59-0.96,p = 0.022)。 C421A和OS之间的关联在统计学上不显着(HR = 0.88,95%CI = 0.67-1.15,p = 0.356)。在ABCB1或ABCC2中测得的其他变量均未与PFS或OS相关。结论:ABCG2中的C421A变体以前被证明与增强的蛋白质降解和药物敏感性有关,在铂+紫杉烷类化学疗法治疗的晚期EOC / PPC专利中与更长的PFS相关。这一发现需要进一步验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号